Additionally, this suggests that FGF21 and GDF15, which are biomarkers of mitochondrial diseases, could be used to follow treatment responses and disease progression/recovery in patients with mitochondrial disease. Here, FGF21 is linked to inborn mitochondrial metabolism disorder.